Non-classical Vitamin D Actions for Renal Protection

Area of Science:

• Nephrology
• Endocrinology
• Gerontology

Background:

• Chronic Kidney Disease (CKD) affects 11% of the global population, significantly increasing cardiovascular mortality risk.
• CKD is associated with accelerated aging and impaired vitamin D metabolism, historically treated with calcitriol to manage secondary hyperparathyroidism (SHPT).
• Recent findings reveal high vitamin D deficiency prevalence in CKD and suggest maintaining 25(OH)vitamin D levels above 23 ng/ml can delay CKD progression.

Purpose of the Study:

• To elucidate the pathogenesis of vitamin D deficiency in CKD.
• To explore the link between impaired vitamin D bioactivation to calcitriol and CKD progression pathways.
• To highlight the need for novel biomarkers to assess interventions targeting CKD progression independently of SHPT.

Main Methods:

• Review of existing literature on vitamin D metabolism and CKD.
• Analysis of the role of the vitamin D endocrine system in CKD pathophysiology.
• Discussion of the limitations of current calcitriol-based therapies.

Main Results:

• Vitamin D deficiency is common in all stages of CKD, independent of calcitriol levels.
• Active vitamin D analogs show survival benefits potentially linked to anti-inflammatory and anti-aging effects, not solely SHPT control.
• Maintaining 25(OH)vitamin D levels is crucial for delaying CKD progression.

Conclusions:

• CKD progression may be driven by molecular pathways activated by defective vitamin D bioactivation, independent of SHPT.
• Calcitriol or its analogs cannot correct underlying vitamin D deficiency.
• Novel biomarkers are needed to evaluate the efficacy of vitamin D and calcitriol interventions in ameliorating CKD progression.